SAB Historical Income Statement

SABSW Stock

USD 0.11 0.04 26.67%

Historical analysis of SAB Biotherapeutics income statement accounts such as Total Revenue of 1.9 M, Other Operating Expenses of 28.5 M, Research Development of 32.1 M or Total Operating Expenses of 27.6 M can show how well SAB Biotherapeutics performed in making a profits. Evaluating SAB Biotherapeutics income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of SAB Biotherapeutics's future profits or losses.

Cash Flow Balance Sheet Income Statement

Covid

Financial Statement Analysis is much more than just reviewing and examining SAB Biotherapeutics latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether SAB Biotherapeutics is a good buy for the upcoming year.

Net Income Gross Profit

Check out World Market Map to better understand how to build diversified portfolios, which includes a position in SAB Biotherapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state.

For more information on how to buy SAB Stock please use our How to Invest in SAB Biotherapeutics guide.

About SAB Income Statement Analysis

SAB Biotherapeutics Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to SAB Biotherapeutics shareholders. The income statement also shows SAB investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).

SAB Biotherapeutics Income Statement Chart

At this time, SAB Biotherapeutics' Depreciation And Amortization is fairly stable compared to the past year. Interest Expense is likely to climb to about 289.4 K in 2025, whereas Interest Income is likely to drop slightly above 80.1 K in 2025.

Selling General Administrative Total Revenue Other Operating Expenses Research Development

Total Revenue

Total revenue comprises all receipts SAB Biotherapeutics generated from the sale of its products or services. The total amount of income generated by the sale of goods or services related to the company's primary operations.

Other Operating Expenses

Other Operating Expenses is the expense which generally does not depend on sales or production quantities of SAB Biotherapeutics. It is also known as SAB Biotherapeutics overhead expenses. Typically these expenses include marketing, rent and utilities, office, leases, and other overhead cost. Expenses incurred from non-core business activities, including administrative and general expenses, but excluding costs directly related to production.

Most accounts from SAB Biotherapeutics' income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into SAB Biotherapeutics current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in SAB Biotherapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state.

For more information on how to buy SAB Stock please use our How to Invest in SAB Biotherapeutics guide.At this time, SAB Biotherapeutics' Depreciation And Amortization is fairly stable compared to the past year. Interest Expense is likely to climb to about 289.4 K in 2025, whereas Interest Income is likely to drop slightly above 80.1 K in 2025.

	2022	2023	2024	2025 (projected)
Depreciation And Amortization	3.3M	3.7M	4.3M	4.5M
Interest Income	71.1K	130.8K	150.5K	80.1K

Depreciation And Amortization Interest Income

SAB Biotherapeutics income statement Correlations

	Net Interest Income	Interest Income	Depreciation And Amortization	Interest Expense	Selling General Administrative	Total Revenue	Gross Profit	Other Operating Expenses	Operating Income	Net Income From Continuing Ops	Ebit	Research Development	Ebitda	Total Operating Expenses	Reconciled Depreciation	Income Before Tax	Total Other Income Expense Net	Net Income	Income Tax Expense	Cost Of Revenue	Selling And Marketing Expenses
Net Interest Income		0.34	0.76	-0.86	0.75	-0.31	-0.38	0.42	-0.99	-0.98	-0.96	0.27	-0.95	0.38	0.75	-0.96	-0.12	-0.96	-0.85	0.78	-0.42
Interest Income	0.34		0.16	0.1	-0.01	-0.92	-0.92	-0.01	-0.39	-0.41	-0.46	-0.78	-0.48	-0.07	0.07	-0.41	-0.16	-0.41	-0.06	0.24	-0.03
Depreciation And Amortization	0.76	0.16		-0.82	0.84	-0.16	-0.24	0.83	-0.83	-0.66	-0.82	0.34	-0.79	0.82	0.94	-0.81	-0.14	-0.8	-0.97	0.96	-0.72
Interest Expense	-0.86	0.1	-0.82		-0.91	-0.15	-0.07	-0.61	0.85	0.8	0.8	-0.69	0.79	-0.6	-0.87	0.83	0.17	0.83	0.92	-0.82	0.57
Selling General Administrative	0.75	-0.01	0.84	-0.91		0.18	0.11	0.84	-0.76	-0.65	-0.75	0.58	-0.73	0.82	0.9	-0.77	-0.27	-0.77	-0.91	0.91	-0.46
Total Revenue	-0.31	-0.92	-0.16	-0.15	0.18		1.0	0.16	0.38	0.39	0.43	0.79	0.45	0.2	-0.03	0.37	0.07	0.38	0.04	-0.14	0.18
Gross Profit	-0.38	-0.92	-0.24	-0.07	0.11	1.0		0.1	0.44	0.45	0.5	0.75	0.51	0.14	-0.11	0.44	0.08	0.45	0.12	-0.22	0.23
Other Operating Expenses	0.42	-0.01	0.83	-0.61	0.84	0.16	0.1		-0.48	-0.27	-0.5	0.36	-0.46	1.0	0.81	-0.49	-0.19	-0.48	-0.78	0.88	-0.46
Operating Income	-0.99	-0.39	-0.83	0.85	-0.76	0.38	0.44	-0.48		0.96	0.98	-0.22	0.97	-0.44	-0.8	0.98	0.14	0.98	0.88	-0.83	0.51
Net Income From Continuing Ops	-0.98	-0.41	-0.66	0.8	-0.65	0.39	0.45	-0.27	0.96		0.95	-0.19	0.96	-0.23	-0.68	0.96	0.2	0.96	0.75	-0.68	0.43
Ebit	-0.96	-0.46	-0.82	0.8	-0.75	0.43	0.5	-0.5	0.98	0.95		-0.14	1.0	-0.46	-0.84	1.0	0.33	1.0	0.85	-0.82	0.57
Research Development	0.27	-0.78	0.34	-0.69	0.58	0.79	0.75	0.36	-0.22	-0.19	-0.14		-0.12	0.39	0.46	-0.21	-0.01	-0.2	-0.49	0.31	-0.28
Ebitda	-0.95	-0.48	-0.79	0.79	-0.73	0.45	0.51	-0.46	0.97	0.96	1.0	-0.12		-0.41	-0.81	1.0	0.35	1.0	0.82	-0.79	0.56
Total Operating Expenses	0.38	-0.07	0.82	-0.6	0.82	0.2	0.14	1.0	-0.44	-0.23	-0.46	0.39	-0.41		0.79	-0.45	-0.15	-0.44	-0.77	0.86	-0.46
Reconciled Depreciation	0.75	0.07	0.94	-0.87	0.9	-0.03	-0.11	0.81	-0.8	-0.68	-0.84	0.46	-0.81	0.79		-0.84	-0.43	-0.84	-0.93	0.91	-0.77
Income Before Tax	-0.96	-0.41	-0.81	0.83	-0.77	0.37	0.44	-0.49	0.98	0.96	1.0	-0.21	1.0	-0.45	-0.84		0.35	1.0	0.85	-0.81	0.57
Total Other Income Expense Net	-0.12	-0.16	-0.14	0.17	-0.27	0.07	0.08	-0.19	0.14	0.2	0.33	-0.01	0.35	-0.15	-0.43	0.35		0.35	0.1	-0.13	0.43
Net Income	-0.96	-0.41	-0.8	0.83	-0.77	0.38	0.45	-0.48	0.98	0.96	1.0	-0.2	1.0	-0.44	-0.84	1.0	0.35		0.85	-0.81	0.56
Income Tax Expense	-0.85	-0.06	-0.97	0.92	-0.91	0.04	0.12	-0.78	0.88	0.75	0.85	-0.49	0.82	-0.77	-0.93	0.85	0.1	0.85		-0.95	0.62
Cost Of Revenue	0.78	0.24	0.96	-0.82	0.91	-0.14	-0.22	0.88	-0.83	-0.68	-0.82	0.31	-0.79	0.86	0.91	-0.81	-0.13	-0.81	-0.95		-0.57
Selling And Marketing Expenses	-0.42	-0.03	-0.72	0.57	-0.46	0.18	0.23	-0.46	0.51	0.43	0.57	-0.28	0.56	-0.46	-0.77	0.57	0.43	0.56	0.62	-0.57

Click cells to compare fundamentals

SAB Biotherapeutics Account Relationship Matchups

SAB Biotherapeutics income statement Accounts

	2020	2021	2022	2023	2024	2025 (projected)
Net Interest Income	(443.0K)	(271.3K)	(230.5K)	(194.3K)	(223.4K)	(234.6K)
Interest Income	26.1K	23.1K	71.1K	130.8K	150.5K	80.1K
Depreciation And Amortization	548.2K	236.6K	3.3M	3.7M	4.3M	4.5M
Interest Expense	469.2K	294.5K	301.6K	315.3K	283.8K	289.4K
Selling General Administrative	6.8M	17.1M	16.4M	23.8M	27.4M	15.0M
Total Revenue	55.2M	60.9M	23.9M	2.2M	2.0M	1.9M
Gross Profit	55.2M	59.2M	20.6M	(1.5M)	(1.4M)	(1.3M)
Other Operating Expenses	34.7M	13.4M	28.9M	40.3M	46.4M	28.5M
Operating Income	20.6M	(13.4M)	(28.9M)	(38.1M)	(34.3M)	(32.6M)
Net Income From Continuing Ops	20.1M	(17.1M)	(18.7M)	(27.2M)	(24.5M)	(23.3M)
Ebit	20.6M	(11.9M)	(18.4M)	(41.9M)	(37.7M)	(35.8M)
Research Development	27.9M	57.2M	36.4M	16.5M	19.0M	32.1M
Ebitda	21.1M	(11.7M)	(15.1M)	(38.1M)	(34.3M)	(32.6M)
Total Operating Expenses	34.7M	13.4M	28.9M	36.6M	42.1M	27.6M
Income Before Tax	20.1M	(17.1M)	(18.7M)	(42.2M)	(38.0M)	(36.1M)
Total Other Income Expense Net	(439.0K)	(3.8M)	10.2M	(4.1M)	(4.7M)	(4.5M)
Net Income	20.1M	(17.4M)	(18.7M)	(42.2M)	(38.0M)	(36.1M)
Income Tax Expense	473.1K	299.9K	25.6K	(2.0)	(1.8)	(1.71)

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

BTC	Bitcoin
TRX	TRON
BNB	Binance Coin

Additional Tools for SAB Stock Analysis

When running SAB Biotherapeutics' price analysis, check to measure SAB Biotherapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy SAB Biotherapeutics is operating at the current time. Most of SAB Biotherapeutics' value examination focuses on studying past and present price action to predict the probability of SAB Biotherapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move SAB Biotherapeutics' price. Additionally, you may evaluate how the addition of SAB Biotherapeutics to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

SAB Historical Income Statement

About SAB Income Statement Analysis

SAB Biotherapeutics Income Statement Chart

Total Revenue

Other Operating Expenses

SAB Biotherapeutics income statement Correlations

SAB Biotherapeutics Account Relationship Matchups

High Positive Relationship

High Negative Relationship

SAB Biotherapeutics income statement Accounts

Also Currently Popular

Additional Tools for SAB Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Gross Profit	+ 1.0	Total Revenue
Total Operating Expenses	+ 1.0	Other Operating Expenses
Ebitda	+ 1.0	Ebit
Income Before Tax	+ 1.0	Ebit
Net Income	+ 1.0	Ebit
Income Before Tax	+ 1.0	Ebitda

Operating Income	- 0.99	Net Interest Income
Net Income From Continuing Ops	- 0.98	Net Interest Income
Income Tax Expense	- 0.97	Depreciation And Amortization
Net Income	- 0.96	Net Interest Income
Income Before Tax	- 0.96	Net Interest Income
Ebit	- 0.96	Net Interest Income